Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure

Dieplinger, Benjamin; Gegenhuber, Alfons; Struck, Joachim; Poelz, Werner; W, Langsteger; Haltmayer, Meinhard; Mueller, Thomas

doi:10.1016/j.cca.2008.10.012

Cited by 37 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As prior cardiovascular disease and cardiovascular SOFA influenced CgA levels and CgA was associated with septic shock during the hospitalization, this biomarker seems to be associated with cardiovascular dysfunction in severe sepsis. Our results for CgA in patients with severe sepsis are in agreement with previous findings of independent prognostic value of CgA in patients with acute coronary syndromes [14][15][16], decompensated heart failure [17], and in a heterogeneous group of ICU patients [27]. The latter study included 120 consecutive patients with critical illness, of whom 70 patients had sepsis.…”

Section: Discussionsupporting

confidence: 81%

“…CgA also reduces circulating catecholamine levels by directly modulating the adrenal medulla nicotinic receptor [6]. Hence, a principal function of CgA seems to be protection against excessive catecholamine secretion [13], which may explain the merit of CgA as an independent prognostic biomarker in patients with acute cardiac disease [14][15][16][17]. Pathology in the adrenergic and cardiovascular system may also affect outcome in severe sepsis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A similar trend was observed for NT-proBNP which increased from 2610 (survivors) to 5112 (decedents) ng/l, and for the C-terminal ET-1 precursor fragment (CT-proET-1), which increased from 72 (survivors) to 120 (decedents) pmol/l [51]. Accordingly, it was suggested in ADHF that the clinical relevance of CgA plasma concentrations is comparable to that of CT-proET-1 and NT-proBNP [51]. Combined analysis of these markers indicated that a higher risk of death occurs when plasma CgA augments together with NT-proBNP, but it is strongly reduced when either marker alone is increased.…”

Section: Acute Destabilized Heart Failuresupporting

confidence: 75%

“…Complementary in vitro experiments on cultured endothelial cells revealed that full-length human CgA triggered a dose dependent secretion of ET-1 [52]. It is unclear whether an alteration of the CgA-ET-1 axis occurs in ADHF [51]. Interestingly, both proteins are expressed by the myocardium and their concentrations increase in the presence of cardiac diseases.…”

Section: Acute Destabilized Heart Failurementioning

confidence: 99%

Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease

Angelone

Mazza²,

Cerra³

2012

CMC

View full text Add to dashboard Cite

Chromogranin A (CgA), a major component of the chromaffin granules, is co-stored and co-released with catecholamines. It is also expressed in extra-adrenal sites, including the heart. In the rat, CgA localizes in atrial myoendocrine cells, associated with Atrial Natriuretic Peptide (ANP), and in the conduction system. In the human heart it is present in the ventricular myocardium, co-localized with B-type NP (BNP). CgA is the precursor of several biologically active peptides generated by proteolytic processing also in the heart. Two of them, vasostatin-1 (VS-1) and catestatin (Cst), inhibit cardiac contraction and relaxation, counter-regulate beta-adrenergic and endothelinergic stimulation, and protect the heart against ischemia/reperfusion damages. Recently, clinical studies have suggested CgA to be involved also in cardiovascular pathologies. High plasma CgA levels were found in hypertension, chronic and acute heart failure, myocardial infarction, decompensated and hypertrophic heart, and acute coronary syndromes. These alterations correlate with those of conventional cardiovascular biomarkers, such as NP and endothelin-1 (ET-1), and have prognostic relevance, being indicative of both severity of the disease and mortality. Accordingly, the current knowledge indicates CgA as a multifaceted peptide in cardiovascular homeostasis. Whether the influence elicited by the protein on both normal and failing heart is beneficial and/or detrimental, as well as its implication in the cardiac neuroendocrine scenario is under intense investigation. This review will focus on: i) the involvement of CgA and its derived peptides in the mechanisms which sustain cardiac function and compensation, ii) CgA clinical relevance, and iii) its putative value as a clinical biomarker.

show abstract

“…Catestatin inhibits the release of catecholamines [31,32]. Serum CgA is elevated in relation to severity of HF [32] and independently predicts mortality in patients with AHF, with highest mortality in the group of patients with concurrent CgA and NT-proBNP elevations [33]. In a study of 1,268 patients with acute coronary syndromes (ACS) from a single coronary care unit, elevated CgA levels on admission were predictive of long-term mortality and rehospitalizations for AHF [34].…”

Section: Neurohormonal Biomarkersmentioning

confidence: 99%

Novel Biomarkers in Acute Heart Failure

Yanavitski

Givertz

2011

Curr Heart Fail Rep

View full text Add to dashboard Cite

Heart failure goes beyond mechanical dysfunction and involves an interplay of multiple pathophysiologic mechanisms, including inflammation, tissue remodeling, neurohormonal and endocrine signaling, and interactions with the renal and nervous systems. This article highlights some novel biomarkers that may aid in diagnosis, treatment, and prognosis of acute heart failure, specifically focusing on ST2, endoglin, galectin-3, cystatin C, neutrophil gelatinase-associated lipocalin, midregional pro-adrenomedullin, chromogranin A, adiponectin, resistin, and leptin and their emerging clinical roles.

show abstract

Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure

Cited by 37 publications

References 27 publications

Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study

Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study

Chromogranin-A: A Multifaceted Cardiovascular Role in Health and Disease

Novel Biomarkers in Acute Heart Failure

Contact Info

Product

Resources

About